Anastrozol ist in Großbritannien zur vorbeugenden Behandlung für Frauen nach der Menopause mit einem moderaten oder hohen Brustkrebsrisiko zugelassen“
Our leading experts continuously support physicians in their clinical decision-making with updated Clinical Practice Guidelines and Consensus Statements from European Society of Medical Oncology (ESMO).
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
